MVI-targeted carbon-ion radiotherapy combined with immunotherapy for advanced hepatocellular carcinoma: Phase Ib DEPARTURE trial - PubMed
4 hours ago
- #carbon-ion radiotherapy
- #hepatocellular carcinoma
- #immunotherapy
- Phase Ib DEPARTURE trial evaluated MVI-targeted carbon-ion radiotherapy combined with immune checkpoint inhibitors (durvalumab ± tremelimumab) for advanced hepatocellular carcinoma with macrovascular invasion.
- No dose-limiting toxicities were observed; the combination had a manageable safety profile with common adverse events including pyrexia, rash, and elevated lipase, and grade 3-4 events in 53.3%.
- Median progression-free survival was 4.7 months and overall survival was 10.4 months, with effective local control of irradiated lesions but limited systemic immune responses in non-irradiated lesions.
- RNA-sequencing showed enriched immune activation pathways in responders, while resistance was linked to mesenchymal and angiogenesis signatures, supporting further investigation of this approach.